ClinicalTrials.gg
RecruitingNCT06582888VRUpdated Mar 16, 2026

Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder

An Early Phase 1 interventional study of Varenicline Tartrate and Placebo in Nicotine Addiction and Craving, sponsored by University of California, San Diego. Recruiting at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by University of California, San Diego · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies testing varenicline in Tobacco Use Disorder — 5 open to participants now, 5 under way, 1 of them phase 3. Varenicline · Tobacco Use Disorder.

Planned enrollment
22nd of 74
200 · median 113
Started
2024
the only one that year
Phase 1
3 of 74
1 open now
Registered
70th of 74
by date

Among the 74 studies testing varenicline in Tobacco Use Disorder, this one is the 22nd largest by planned enrollment, is the only one that started in 2024, is one of 3 in phase 1, and was the 70th registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

5 of the 74 studies testing varenicline in Tobacco Use Disorder are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies testing varenicline in Tobacco Use Disorder, or all of them as a file.
02

Study summary

The proposed project will include enrollment of 200 daily tobacco cigarette users, ages 22+, from the San Diego community. Participants will be assessed on the VR Nicotine Cue Exposure paradigm then randomized (stratified on age and sex) to receive varenicline (target dose 1mg twice daily) or placebo (n per group=100; total N=200). Following eight days of titration, participants will be assessed again on the VR Nicotine Cue Exposure paradigm. They will then be followed via mobile assessments for eight days on target dose of varenicline, and 30-days post assessment by phone, to assess short-term nicotine use behaviors.

03

Conditions studied

  • Nicotine Addiction
  • Craving
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Persons, aged 22+
  4. Ability to take oral medication and be willing to adhere to the dosing regimen
  5. For participants able to become pregnant: use of highly effective during study enrollment
  6. Current daily tobacco use (use on 7 days per week, on average, ≥5 cigarettes per day, in the previous 3 months)
  7. Tobacco use history ≥3 years
  8. Endorsement of past week nicotine craving

Exclusion criteria

Exclusion Criteria:

  1. /conditions with special precautions for varenicline treatment (i.e., history of serious or skin reactions to varenicline, history of severe renal impairment, seizures, severe cardiovascular disease, chronic or severe nausea, Stevens-Johnson syndrome, erythema multiforme, pregnancy or nursing)
  2. Medical or psychiatric history affecting brain development (i.e., history and/or treatment of neurologic disorders, severe head trauma with loss of consciousness >2 minutes, or current severe Diagnostic and Statistical Manual 5th edition () psychiatric disorders other than tobacco use disorders)
  3. Current suicidal ideation or history of suicide attempt or self-mutilatory acts in the past 12 months
  4. Other recreational drug use in the past 30 days (besides alcohol and cannabis) verified by oral and urine fluid toxicology
  5. Visual/vestibular problems that may make task completion difficult (i.e., motion sickness, difficulty balancing, blindness)
  6. Treatment seeking for tobacco use disorder/intent to quit within 30 days
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Varenicline

    Following the baseline assessment, participants randomized to receive varenicline will complete an 8-day titration period to achieve the target dose. Titration of varenicline will be as follows: 0.5 mg once daily for Days 1-3, 0.5 mg twice daily for Days 4-7, and 1 mg twice daily on Day 8. Participants then return to the lab on Day 9 (or Days 10, 11 if necessary) for testing at the target dosage (1 mg twice daily) and continue at that dose for eight additional days (Days 10-17) for mobile monitoring.

    Drug: Varenicline Tartrate

  • Placebo comparator
    Placebo

    Following the baseline assessment, participants randomized to receive placebo pill will follow the same dosing schedule as the active arm. They will return to the lab on Day 9 (or Days 10, 11 if necessary) for testing and continue at that dosing schedule for eight additional days (Days 10-17) for mobile monitoring.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Virtual Reality Attentional Bias (VR-AB) pre- and post-treatment

    Eye gaze fixation time to active versus neutral cues from the \"NTP Cue VR Paradigm\"

    Time frame: during each in-person session, at baseline and on average 8 days post baseline assessment

  2. Nicotine craving

    Assessed via the Tobacco Craving Questionnaire - Short-Form

    Time frame: during each in-person session, at baseline and on average 8 days post baseline assessment

  3. Nicotine craving

    Assessed via visual analogue scales (VR paradigm and mobile surveys)

    Time frame: through study completion, an average of 30 days

  4. Nicotine use episodes

    Assessed via the Timeline Followback

    Time frame: during each in-person session, at baseline and on average 8 days post baseline assessment

  5. Nicotine use episodes

    Assessed via participant fill-in on mobile surveys

    Time frame: through study completion, an average of 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Psychophysiology, mental health, and substance use de-identified data listed above sufficient in quality to validate and replicate the research findings described in the aims will be deposited to the National Addiction \& HIV Data Archive Program (NAHDAP) repository. For specific variables where small sample sizes may allow for easy re-identification of research participants, only summarized data will be made available.

Supporting information: Informed consent form, Analytic code

Time frame: Data will become available 2025-2028

Access criteria: Standard procedures of the NAHDAP will be followed for determining the best level of access (public or restricted) based on review of disclosure risk by ICPSR.

Data sharing details ↗ · www.icpsr.umich.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Aug 2028, 44 months after the start.

Of 39 non-industry phase 1 interventional studies under Tobacco Use Disorder, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 44 months is above that.

Counting every sponsor, half of 45 studies reached it within 20 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Sep 3, 2024
StartActual
Nov 19, 2024
Primary completionEst.
Aug 15, 2028
CompletionEst.
Aug 15, 2028
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06582888
Responsible party
Kelly Courtney (Assistant Adjunct Professor, Psychiatry, University of California, San Diego) — Principal investigator
First posted
Sep 3, 2024
Start date
Nov 19, 2024
Primary completion
Aug 15, 2028 (estimated)
Completion
Aug 15, 2028 (estimated)
Last update
Mar 16, 2026

Study contacts

Research Coordinator
Contact
vrstudy@health.ucsd.edu
858-480-1251
Kelly Courtney, Ph.D.
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion